R L Piekarz

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
    R L Piekarz
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 98:2865-8. 2001
  2. ncbi Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
    Richard L Piekarz
    Departmentof Health and Human Services, Center for Cancer Researchand Cancer Therapy EvaluationProgram, National Cancer Institute, National Institutes of Health, Bethesda, USA
    J Clin Oncol 27:5410-7. 2009
  3. ncbi Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy
    Richard L Piekarz
    Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1903, USA
    Cancer J 13:30-9. 2007
  4. ncbi Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
    Richard L Piekarz
    Center for Cancer Research and Cancer Therapeutics Evaluation Program, National Cancer Institute and National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20892 1903, USA
    Clin Cancer Res 12:3762-73. 2006
  5. ncbi Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
    Richard L Piekarz
    Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health DHHS, 6130 Executive Blvd, Rockville, MD 20852, USA
    Blood 117:5827-34. 2011
  6. ncbi T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
    Richard L Piekarz
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute NIH, MSC 1903, 10 Center Drive, Building 10 Room 12C103, Bethesda, MD 20892 1903, USA
    Blood 103:4636-43. 2004
  7. ncbi Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
    Robert W Robey
    Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 12:1547-55. 2006
  8. ncbi New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1868, USA
    Clin Cancer Res 16:5608-17. 2010
  9. ncbi Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    Susan E Bates
    Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 148:256-67. 2010
  10. ncbi Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?
    Susan E Bates
    Molecular Therapeutics Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer J 13:80-3. 2007

Collaborators

Detail Information

Publications16

  1. ncbi Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
    R L Piekarz
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 98:2865-8. 2001
    ..Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma...
  2. ncbi Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
    Richard L Piekarz
    Departmentof Health and Human Services, Center for Cancer Researchand Cancer Therapy EvaluationProgram, National Cancer Institute, National Institutes of Health, Bethesda, USA
    J Clin Oncol 27:5410-7. 2009
    ..The median duration of response was 13.7 months. CONCLUSION The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL...
  3. ncbi Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy
    Richard L Piekarz
    Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1903, USA
    Cancer J 13:30-9. 2007
    ..In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents...
  4. ncbi Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
    Richard L Piekarz
    Center for Cancer Research and Cancer Therapeutics Evaluation Program, National Cancer Institute and National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20892 1903, USA
    Clin Cancer Res 12:3762-73. 2006
    ....
  5. ncbi Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
    Richard L Piekarz
    Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health DHHS, 6130 Executive Blvd, Rockville, MD 20852, USA
    Blood 117:5827-34. 2011
    ..The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL...
  6. ncbi T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
    Richard L Piekarz
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute NIH, MSC 1903, 10 Center Drive, Building 10 Room 12C103, Bethesda, MD 20892 1903, USA
    Blood 103:4636-43. 2004
    ..These studies confirm the activity of depsipeptide in a T-cell lymphoma model and suggest a general sensitivity of T-cell lymphoma to histone deacetylase inhibitors, an emerging new class of anticancer agents...
  7. ncbi Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
    Robert W Robey
    Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 12:1547-55. 2006
    ..These studies suggest that depsipeptide induces its own mechanism of resistance and thus provide a basis for clinical trials evaluating depsipeptide in combination with a Pgp inhibitor...
  8. ncbi New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1868, USA
    Clin Cancer Res 16:5608-17. 2010
    ..In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL...
  9. ncbi Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    Susan E Bates
    Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 148:256-67. 2010
    ....
  10. ncbi Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?
    Susan E Bates
    Molecular Therapeutics Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer J 13:80-3. 2007
  11. ncbi Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
    Sukyung Woo
    Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:1496-503. 2009
    ..The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma...
  12. ncbi Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry
    Kyunghwa Hwang
    Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 809:81-6. 2004
    ..The values for precision and accuracy were always < or =7.88% and <3.33% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of FK228 in a cancer patient...
  13. ncbi Epigenetic modifiers: basic understanding and clinical development
    Richard L Piekarz
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:3918-26. 2009
    ..This issue of CCR Focus is dedicated to understanding the clinical and translational aspects of epigenetics research...
  14. ncbi Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
    Victor Sandor
    McGill University, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    Clin Cancer Res 8:718-28. 2002
    ..Biologically active serum concentrations were achieved, and 1 patient obtained a partial response. The recommended Phase II dose is 17.8 mg/m(2) administered on day 1 and 5 of a 21-day cycle...
  15. ncbi Effect of a histone deacetylase inhibitor on human cardiac mass
    Yukitaka Shizukuda
    Cardiovasc Drugs Ther 19:89-90. 2005
  16. ncbi Challenges of evaluating the cardiac effects of anticancer agents
    Susan E Bates
    Clin Cancer Res 12:3871-4. 2006